Firmagon (degarelix)

Degarelix or Leuprolide – Today’s Question Explored

There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to suppress testosterone. What makes this class of drugs different is that it also avoids the flare phenomenon that is observed with the GnRH agonists like Lupron. The flare phenomenon, where the body initially pumps out additional levels of testosterone in response to the GnRH agonist [...]

How To Have A Firmagon Injection And Minimized The Side Effects

Three of the participants on the Malecare Health Unlocked Advanced Prostate Cancer Online Support Group have been sharing their personal experiences and recommendations on how to best get a Firmagon injection. It is clear that how the injection is given has a direct effect on he pain and inflammation a man will experience from the injection. If you are getting ready to start Firmagon you should heed these recommendations. Dave 2 said, “My experience w/ Firmagon was similar to yours--initial doses to stomach area but at too shallow an angle. This med is very dependent on skill of nurse administering [...]

German Registry Data Analysis of Degarelix (Firmagon®) for Prostate Cance

The newest gonadotropin-releasing hormone (GnRH) antagonist therapy drug, degarelix (aka Firmagon) has become more commonly used in everyday clinical practice as an alternative hormone therapy treatment drug (ADT). Given that its use has become common it is important to understand both its safety and efficacy as compared to our older standard drugs. The best way to track this type of information is through a registry. This was done when researchers, using the registry data from uro-oncology practices in Germany, retrospectively analyzed the information contained in the IQUO (Association for uro-oncological quality assurance) patient registry. They evaluated data prospectively collected from [...]

Metabolic Syndrome in Men with Castration-Resistant Prostate Cancer Treated with Abiraterone Affects Their Survival

Yesterday’s post was about the increased risks of developing diabetes faced by men who are on hormone therapy. This study, as well as most others about this topic has looked at the first levels of hormone therapy (ADT) using the traditional drugs like Zoladex, Trelstar, Firmagon, and Lupron. We know very little about the influence on survival that the newer hormone manipulations like abiraterone (Zytiga), which has become one of the standard of care drugs for men who also have castrate resistant metastatic prostate cancer (mCRPC), has on men with diabetes or metabolic syndrome (a precursor to diabetes). A recent [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー